Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Histogen

NeuroBo Pharmaceuticals Inc

Are biotech penny stocks on your buy list right now The post Buying Biotech Penny Stocks? 3 Things to Look For  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Buying Biotech Penny Stocks? 3 Things to Look For

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Thomas Hong – Manager-Investor Communications Jacque Shea – President and Chief Executive Officer Michael Sumner – Chief Medical Officer Peter Kies – Chief Financial Officer Conference Call Participants Hartaj Singh – Oppenheimer & Company Operator Good day and welcome to the Inovio Third Quarter 2022 Results Conference Call. [Operator instructions] Please note that this event is being recorded.

Inovio Pharmaceuticals, Inc. (INO) Q3 2022 Earnings Call Transcript

Inovio (INO) delivered earnings and revenue surprises of 48.28% and 3,880%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates

Announced positive interim data for INO-3107 as a potential first-in-class treatment for Recurrent Respiratory Papillomatosis Advanced strategy to focus on developing candidates that have the greatest opportunity for near-term success Updates prior financial guidance and extends cash runway into first quarter of 2025 Company will hold investor call today at 4:30 PM ET PLYMOUTH MEETING, Pa. , Nov. 8, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today reported financial results for the quarter and nine months ended September 30, 2022.

INOVIO Reports Financial Results and Highlights for the Third Quarter 2022

The biotech is ceasing its internally funded efforts to develop a heterologous coronavirus booster.

Why Inovio Pharmaceuticals Stock Zoomed Nearly 6% Higher Today

PLYMOUTH MEETING, Pa. , Oct. 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine.

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800

PLYMOUTH MEETING, Pa. , Oct. 25, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, announced today that third quarter 2022 financial results will be released after the market close on November 8, 2022.

INOVIO to Report Third Quarter 2022 Financial Results on November 8, 2022

The stock jumped Monday despite no news from the company.

Why Inovio Pharmaceuticals' Shares Jumped 17.31% on Monday

Treatment with INO-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no surgical intervention during the trial INO-3107 demonstrated statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous year INO-3107 was found to be well-tolerated and immunogenic PLYMOUTH MEETING, Pa. , Oct. 13, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.

INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 7:00 AM ET Company Participants Jacqueline Shea - President and CEO Conference Call Participants Brooke Katsof - H.C.

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 24th Annual Global Investment Conference (Transcript)

Can the company still count on its coronavirus-related efforts?

1 Green Flag and 1 Red Flag For Inovio Pharmaceuticals

PLYMOUTH MEETING, Pa. , Aug. 30, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that Jacqueline Shea, Ph.D.

INOVIO to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Its newly announced cost-saving measures are getting a warm reception.

Why Inovio Pharmaceuticals Is Gaining Today

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Thomas Hong - IR Jacqueline Shea - CEO, President & Director Michael Sumner - Chief Medical Officer David Liebowitz - SVP, Clinical Development Jeffrey Skolnik - SVP, Clinical Development Peter Kies - CFO Conference Call Participants Alexandria Hammond - Bank of America Merrill Lynch Gregory Renza - RBC Capital Markets Jiale Song - Jefferies Eka Gigauri - Oppenheimer Raghuram Selvaraju - H.C. Wainwright & Co. Yi Chen - H.C.

Inovio Pharmaceuticals, Inc. (INO) CEO Jacqueline Shea on Q2 2022 Results - Earnings Call Transcript

Increased Cash Runway into Third Quarter 2024 with Cost-Savings and Corporate Restructuring Efforts  Strengthened Executive Team with Appointment of Dr. Michael Sumner as Chief Medical Officer  Announced Positive Data from a Phase 1/2 Trial with INO-5401 to treat Glioblastoma (GBM) at the American Society of Clinical Oncology (ASCO) Annual Meeting  Will hold investor call today at 4:30 PM EDT PLYMOUTH MEETING, Pa. , Aug. 9, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today reported financial results for the quarter and six months ended June 30, 2022.

INOVIO Reports Financial Results and Highlights for the Second Quarter 2022

Amgen

Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles

Two Appealing Biotech Stocks for Two Distinct investors

Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

PLYMOUTH MEETING, Pa. , July 26, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, announced today that second quarter 2022 financial results will be released after the market close on August 9, 2022.

INOVIO to Report Second Quarter 2022 Financial Results on August 9, 2022

SIGA Technologies

The World Health Organization has declared monkeypox a global health emergency amid more than 16,000 cases globally and five deaths.

Health Chiefs Sound the Alarm on Monkeypox. These Vaccine Stocks Are Soaring.

The last few years haven't been kind to Inovio Pharmaceuticals.

1 Beaten-Down Growth Stock To Avoid Like the Plague

It's betting on success as a vaccine latecomer.

After Slashing Costs, Is Inovio a Buy?

RBC Capital Markets has lowered the price target on Inovio Pharmaceuticals Inc (NASDAQ: INO) to $4 from $5 with a Sector Perform rating. The analysts updated the model to reflect the evolution of the programs to date and as new leadership gained traction since the CEO change in.

RBC Capital Lowers Inovio Price Target As It Awaits This

Inovio Pharmaceuticals Inc. INO, -6.60% said Tuesday that it plans to reduce its full-time workforce by 18% and its contractor workforce by 86% in an effort to extend its cash runway. The company had 317 full-time employees in 2021.

Inovio to reduce its workforce by 18%

Changes expected to reduce operational expenses and extend the company's cash runway into third quarter of 2024 Improving cost structure will allow company to focus on strategic priorities, including heterologous boost strategy for COVID-19 vaccine candidate and HPV programs PLYMOUTH MEETING, Pa. , July 19, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, announced that it has implemented a corporate reorganization designed to extend its cash runway and to focus on key clinical programs with the goal to drive long-term growth.

INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients

PLYMOUTH MEETING, Pa. , July 1, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that in connection with the hiring of Dr. Michael John Sumner as Chief Medical Officer, announced on June 27, 2022, the Compensation Committee of INOVIO's Board of Directors approved equity grants to Dr. Sumner as inducement awards under INOVIO's 2022 Inducement Plan (the "Inducement Plan").

News for Inovio Pharmaceuticals Stock (INO)